Physician profile
Steven Frey
NPI 1285293670
$1,848.83
in general payments reported to CMS, 2019-2025
26 companies · $920 in 2025
The $920 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $12.05 · 2024: $917 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $468.68 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $365.97 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Corium, LLC | $155.30 | 2024-2025 | Azstarys |
| Exact Sciences Corporation | $105.18 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $79.23 | 2025 | |
| Phathom Pharmaceuticals, INC. | $75.67 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $64.78 | 2025 | Veozah |
| Dexcom, INC. | $64.27 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $61.99 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Avvisto Therapeutics, LLC | $53.44 | 2025 | Cycloset |
| Antares Pharma, INC. | $50.06 | 2024 | Xyosted |
| Glaxosmithkline, LLC. | $29.71 | 2024-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $29.31 | 2024-2025 | |
| Abbvie INC. | $28.27 | 2024 | |
| Itamar Medical INC | $26.40 | 2024 | Watchpatone |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23.04 | 2025 | Epclusa |
| Axsome Therapeutics, INC. | $20.88 | 2024 | Auvelity |
| Lilly USA, LLC | $20.00 | 2025 | Jardiance |
| Ardelyx, INC. | $18.68 | 2024 | Ibsrela |
| Spr Therapeutics, INC | $18.05 | 2024 | Sprint Pns System |
| Dynavax Technologies Corporation | $17.15 | 2025 | Heplisav-B |
| Amgen INC. | $16.33 | 2025 | Krystexxa |
| Sumitomo Pharma America, INC. | $16.13 | 2024 | Gemtesa |
| Seqirus USA INC | $14.79 | 2025 | Fluad, Flucelvax |
| Tolmar, INC. | $13.47 | 2025 | Jatenzo |
| Organon LLC | $12.05 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.